CAM
EBS icon

ClariVest Asset Management’s Emergent Biosolutions EBS Stock Holding History

ClariVest Asset Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-51,724
Closed -$4.8M – 773
2021
Q1 		$4.8M Buy
51,724
+15,000
+41% +$1.54M 0.17% 118
2020
Q4 		$3.29M Sell
36,724
-20,177
-35% -$1.85M 0.11% 159
2020
Q3 		$5.88M Sell
56,901
-2,452
-4% -$264K 0.19% 96
2020
Q2 		$4.69M Buy
59,353
+874
+1% +$65.1K 0.13% 119
2020
Q1 		$3.38M Buy
58,479
+20,979
+56% +$1.21M 0.1% 131
2019
Q4 		$2.02M Sell
37,500
-24,948
-40% -$1.35M 0.05% 248
2019
Q3 		$3.27M Sell
62,448
-31,700
-34% -$1.48M 0.07% 200
2019
Q2 		$4.55M Sell
94,148
-71,600
-43% -$3.43M 0.1% 170
2019
Q1 		$8.37M Sell
165,748
-8,219
-5% -$485K 0.17% 128
2018
Q4 		$10.3M Buy
173,967
+26,304
+18% +$1.7M 0.22% 92
2018
Q3 		$9.72M Sell
147,663
-28,127
-16% -$1.64M 0.17% 95
2018
Q2 		$8.88M Buy
175,790
+43,689
+33% +$2.28M 0.15% 121
2018
Q1 		$6.96M Buy
132,101
+8,989
+7% +$448K 0.12% 148
2017
Q4 		$5.72M Buy
123,112
+38,679
+46% +$1.63M 0.1% 167
2017
Q3 		$3.42M Buy
84,433
+20,842
+33% +$754K 0.08% 221
2017
Q2 		$2.16M Sell
63,591
-43
-0.1% -$1.33K 0.05% 276
2017
Q1 		$1.85M Hold
63,634
– – 0.05% 289
2016
Q4 		$2.09M Sell
63,634
-62
-0.1% -$1.86K 0.06% 259
2016
Q3 		$2.01M Sell
63,696
-27,673
-30% -$804K 0.06% 212
2016
Q2 		$2.57M Buy
91,369
+12,200
+15% +$478K 0.08% 165
2016
Q1 		$2.88M Sell
79,169
-5,546
-7% -$196K 0.09% 144
2015
Q4 		$3.39M Sell
84,715
-2,011
-2% -$70.1K 0.1% 121
2015
Q3 		$2.47M Sell
86,726
-2,000
-2% -$65.9K 0.07% 163
2015
Q2 		$2.92M Sell
88,726
-7,911
-8% -$245K 0.09% 157
2015
Q1 		$2.78M Sell
96,637
-1,126
-1% -$32.3K 0.08% 146
2014
Q4 		$2.66M Sell
97,763
-480
-0.5% -$11.4K 0.09% 123
2014
Q3 		$2.09M Buy
98,243
+3,606
+4% +$82.6K 0.08% 170
2014
Q2 		$2.13M Sell
94,637
-22,878
-19% -$533K 0.08% 169
2014
Q1 		$2.97M Buy
117,515
+79,635
+210% +$2.01M 0.12% 120
2013
Q4 		$871K Buy
+37,880
New +$790K 0.04% 230

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $128B AUM 35.83% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ClariVest Asset Management's EBS Position: Q2 2021 in Review

ClariVest Asset Management sold out of Emergent Biosolutions (EBS) in Q2 2021, closing a stake of 51,724 shares — an estimated $4.8M sold.

ClariVest Asset Management first reported a position in EBS in Q4 2013 and held it in 30 quarters. The position peaked at $10.3M in Q4 2018. 290 funds tracked by Wall St. Rank hold EBS as of Q2 2021.

  • ClariVest Asset Management reported no remaining Emergent Biosolutions position as of Q2 2021 after selling out during the quarter.
  • ClariVest Asset Management sold 51,724 Emergent Biosolutions shares in Q2 2021, an estimated $4.8M.
  • ClariVest Asset Management first reported a position in Emergent Biosolutions in Q4 2013 and held it in 30 quarters.
  • ClariVest Asset Management's Emergent Biosolutions position peaked at $10.3M in Q4 2018.
  • 290 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2021.

Based on ClariVest Asset Management's 13F filing for Q2 2021, filed 9 Aug 2021.